The Safe Response Act amends Section 546 of the Public Health Service Act (42 U.S.C. 290ee–1) to broaden the federal first responder training program. It strips multiple references that limited the program to opioids, explicitly allows training and materials addressing other drugs and general overdoses, and expands device/drug language from "approved or cleared" to "approved, cleared, or otherwise legally marketed." The bill also reauthorizes and increases annual funding to $57,000,000 for each of fiscal years 2026 through 2030.
This is a focused statutory update with three practical effects: 1) it widens the training curriculum beyond opioid response to include other drug poisonings, 2) it relaxes regulatory language about which countermeasures grantees may use or teach about, and 3) it increases funding for grants. Compliance officers, public health planners, and procurement teams should prepare for new training content, broader product options, and updated grant budgeting and reporting requirements.
At a Glance
What It Does
The bill amends 42 U.S.C. 290ee–1 (Section 546) to remove opioid-specific terminology, permit training on "other drug" overdoses and general "overdose," and replace the phrase "approved or cleared" with "approved, cleared, or otherwise legally marketed." It also authorizes $57 million per year for FY2026–2030.
Who It Affects
State, local, and Tribal health agencies that receive Section 546 grants; first responder organizations and their training vendors; manufacturers and distributors of overdose reversal products; and HHS offices that administer and monitor the program.
Why It Matters
The changes expand what grantees can train on and which market-available products they can incorporate, shifting procurement and curriculum decisions. The funding increase creates room to scale training but also raises expectations for broader program scope and oversight.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Safe Response Act is a targeted reauthorization and scope change for the federal first responder training program established in Section 546 of the Public Health Service Act. Rather than limiting the program to opioid-specific response, the bill replaces several statutory references to "opioid" with broader language—most notably turning "opioid overdose" into simply "overdose" and expanding "opioid and heroin" to "opioid, heroin, and other drug." In plain terms, grant-funded training can now legally cover stimulant, sedative, or polysubstance incidents in addition to opioid events.
On the procurement and tool side, the bill replaces the narrower phrase "approved or cleared" with "approved, cleared, or otherwise legally marketed." That wording broadens the set of medications or devices grantees can teach about or supply to responders to include any product that is lawfully on the U.S. market even if it does not fall neatly under the old approval/clearance labels. Practically, this can affect which nasal sprays, injectables, or other countermeasures appear in curricula and field kits.The bill also updates funding: instead of the prior authorization level tied to FY2019–2023, it sets a flat authorization of $57 million per year for FY2026–2030.
That increase is intended to support a larger or more intensive program, but the statute leaves the programmatic details—allocation formulas, allowable grant activities beyond training, and performance measures—to the administering agency.Finally, the changes include a minor technical edit to capitalization of "Tribes and Tribal" in subsection (a). While small, it signals continued inclusion of Tribal entities as authorized recipients.
The act is narrowly written: it does not create new grant categories or change enforcement mechanisms, but it does enlarge subject matter and permissible products within the existing grant framework.
The Five Things You Need to Know
The bill amends Section 546 of the Public Health Service Act (42 U.S.C. 290ee–1).
It replaces statutory references to "opioid overdose" with the broader term "overdose," and changes "opioid and heroin" to "opioid, heroin, and other drug.", It changes the device/drug eligibility phrasing from "approved or cleared" to "approved, cleared, or otherwise legally marketed," widening what products grantees may incorporate.
Subsection (f) receives multiple content edits that explicitly allow training on non-opioid drug events and general overdose response, not just opioid/heroin.
It authorizes $57,000,000 for each of fiscal years 2026 through 2030 (replacing the prior $36,000,000 per-year authorization for 2019–2023).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Scope and recipient language — includes Tribes and broadens subject matter
This subsection sets program scope and identifies eligible recipients. The bill corrects capitalization to "Tribes and Tribal," a technical edit that preserves Tribal eligibility while signaling statutory attention to Tribal partners. More substantively, other amendments in the act operate against the scope established here: by erasing opioid-only language elsewhere, the program's subject matter implicitly expands beyond opioids while keeping the same recipient universe (states, localities, Tribes, and authorized entities).
Permissible countermeasures — broadened regulatory phrasing
These subsections previously required that training materials and distributed countermeasures be "approved or cleared." The act inserts "approved, cleared, or otherwise legally marketed," which enlarges the set of products grantees may use. In practice, HHS will need to interpret what "otherwise legally marketed" includes (e.g., over-the-counter products, products marketed under different statutory pathways, or state-authorized formulations) when issuing guidance or evaluating grantee compliance.
Training content — expands beyond opioid/heroin response to other drugs and general overdoses
Subsection (f) governs the program's training topics. The bill removes narrow references to "opioid" and replaces mentions of "opioid and heroin" with "opioid, heroin, and other drug," and changes "opioid overdose" to "overdose." Those edits authorize curricula that address stimulant-related toxicity, benzodiazepine-involved events, polysubstance overdose recognition, and other non-opioid emergencies. Training providers will need to update learning objectives, clinical protocols, and simulation scenarios to reflect this broader remit.
Funding authorization — increases annual appropriation through 2030
This provision replaces the prior authorization level ($36 million per year for FY2019–2023) with $57 million annually for FY2026–2030. The statutory change sets the ceiling for congressional appropriations; it does not itself appropriate funds or prescribe allocation formulas. Administrators and grantees should expect a larger program budget but must await agency guidance on how increased dollars will be distributed and prioritized.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- First responders (EMS, police, fire): They receive federally authorized training covering a wider array of overdose types and response techniques, improving readiness for non-opioid and polysubstance incidents.
- State and local public health departments: Expanded statutory scope lets health departments design grant-funded programs that address local overdose profiles beyond opioids, and increased authorization levels create capacity to expand training and supply distribution.
- Tribal governments and Tribal health organizations: The statutory text retains Tribal eligibility and the higher funding authorization increases potential resources available to Tribal programs addressing diverse overdose threats.
- Manufacturers and distributors of legally marketed countermeasures: The "otherwise legally marketed" language broadens which products may be incorporated into training and field kits, potentially opening market access for products not previously captured by the narrower "approved or cleared" label.
Who Bears the Cost
- HHS (grant administrator, likely CDC or HRSA): The agency must interpret "otherwise legally marketed," develop new guidance, and expand monitoring and technical assistance, increasing administrative workload without accompanying earmarked implementation language.
- Grantees and training providers: Programs will need to redesign curricula, retrain instructors, procure additional or different countermeasures, and possibly expand training hours—costs that may not be fully covered by grant awards.
- Procurement and logistics teams in states and localities: Broader allowable products increase procurement complexity and create new inventory, storage, and chain-of-custody considerations for non-opioid countermeasures.
- Legal/compliance offices for agencies and suppliers: Broader product language raises questions about liability, indemnification, and quality standards for "otherwise legally marketed" items, requiring legal review and possible contract revisions.
Key Issues
The Core Tension
The central tension is between saving more lives by broadening training and product options versus protecting quality and safety: expanding scope and permissible countermeasures increases potential coverage of diverse overdoses but creates ambiguity about which drugs to prioritize, how to train responders across multiple clinical scenarios, and how to ensure that "legally marketed" products meet adequate safety and effectiveness standards.
The bill trades a narrowly targeted opioid-response program for a broader overdose-response mandate without adding detailed implementation rules. That leaves HHS with significant discretion to define both the breadth of "other drug" content and what counts as "otherwise legally marketed" for program supplies.
Practically, that creates ambiguity for grantees deciding which products to include in training and kits and for manufacturers seeking clarity on whether their products fit the statute.
Expanding content to cover stimulants, benzodiazepines, and polysubstance events also raises pedagogical and clinical questions: countermeasures and response protocols differ across drug classes, so a single training model may struggle to achieve clinical competence across all scenarios. The authorization of $57 million per year increases resources, but the statute does not specify allocation methods, minimum awards, or evaluation metrics—leaving potential gaps between the program's broader goals and the money actually reaching front-line training.
Finally, the broadened product language may increase legal exposure for grantees if they adopt products with less uniform regulatory review; agencies will need to balance access with prudent quality controls and liability protections.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.